Daidzein reverses TRAIL-resistance in LNCaP prostate cancer stimulating the decrease in the MMP and in LN229 glioma cells activating caspase-9 and downregulating of bcl-2 [73–76]. The gene discussed is BCL2; the disease is central nervous system cancer.